Home › Trial NCT06406816
Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection
- Trial IDNCT06406816
- StatusRecruiting
- PhaseEarly Phase 1
- Study typeInterventional
- SponsorYongyi Zeng
- Enrollment10
- Start date2024-05-06
- ConditionsIntrahepatic Cholangiocarcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.